NACDS debuts new app for 2011 Marketplace Conference
ALEXANDRIA, Va. — The National Association of Chain Drug Stores has launched its 2011 Marketplace Web-based mobile application, which is designed to enhance attendees’ efficiency and experience at the NACDS Marketplace Conference from June 25 to 28 in Boston.
The first NACDS mobile app was introduced for the NACDS 2010 Annual Meeting.
In addition, the NACDS mobile website, m.NACDS.org, is updated with information about the upcoming conference and all 2011 NACDS events.
"NACDS continues to explore innovative ways to enhance its member programs and services," NACDS president and CEO Steve Anderson said. "Utilizing technology is an important way to maximize the continued value and experience that NACDS members expect from NACDS meetings and conferences."
The NACDS mobile app is compatible with most smartphone platforms, including iPhone, Droid and Blackberry devices, and can be downloaded for free on m.NACDS.org or from NACDS’ main website, NACDS.org. The NACDS mobile website serves as a "guide on the go" to NACDS meetings, advocacy and communications. Marketplace attendees will find planning tools for the event, including an updated schedule, floor plan, list of participants and sponsors.
The site is specifically designed for ease of use on any smartphone with a Web browser.
Abbott: LCIG may improve Parkinson’s disease symptoms among patients
ABBOTT PARK, Ill. — Patients with Parkinson’s disease treated with an investigational drug made by Abbott saw a decrease in the amount of time their symptoms resurfaced, while the time in which their symptoms stayed under control increased, according to results of a late-stage clinical trial that Abbott announced Thursday.
The 192-patient trial was a 54-week, phase-3 study of levodopa-carbidopa intestinal gel, or LCIG. As Parkinson’s patients’ disease progresses during treatment with oral medications, they usually will experience “off” time, when some of their symptoms re-emerge. This contrasts with “on” time, when their symptoms are well-managed. They also may experience involuntary movements associated with most treatments used to manage the disease, known as dyskinesias, which can result from spikes in drug levels in the blood caused by inconsistent absorption of oral medications.
After 12 weeks of therapy, patients reported an average of 3.9 fewer hours of “off” time and 4.6 more hours of “on” time without troublesome dyskinesias.
LCIG is infused with a portable pump directly into the small intestine via a small tube during daytime hours, and continuous delivery may help reduce drug-level spikes, thus reducing dyskinesias.
FDA approves labeling change for Eli Lilly insulin product
INDIANAPOLIS — Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.
The FDA approved changes to the labeling of Humalog (insulin lispro [rDNA origin]) that allows continuous insulin infusion pump therapy in children ages 4 years and older with Type 1 diabetes. Additionally, the insulin can remain in the external pump reservoir for seven days, and patients now can wait three days before changing the infusion set and infusion set insertion site, Lilly said.
“Insulin pumps can be an additional option for people using rapid-acting insulin, and allow people to manage their Type 1 diabetes around their lifestyle,” Lilly clinical research physician Dana Hardin stated. “These Humalog label updates reflect Lilly Diabetes’ commitment to providing people with personalized solutions that meet their everyday needs.”